Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors

Peking University

Status and phase: Unknown; Phase 4

Conditions: Lymphoma

Treatments: Other: Hematopoietic stem cell transplantation

Study type: Interventional

Funder types: Other

Identifiers

NCT02929615

v1.0-20150805

Details and patient eligibility

About

The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.

Enrollment: 50 estimated patients

Sex: All

Ages: Under 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with relapse and refractory lymphoma and multiple myeloma.
2. At least 1 measurable lesions and its size≥15mm.
3. Patients ≤65 years，no limitations for both gender.
4. ECOG score is 0-1.
5. Life expectancy≥3 months.
6. LVEF≥ 55%; Peripheral blood: WBC ≥ 3.5×10(9)/L,neutrophil ≥1.5×10(9)/L, PLT≥75×109/L，Hb≥90g/L; Renal function: Cr≤2.0×UNL; Liver function: BIL≤2.0×UNL，ALT/AST≤2.5×UNL;
7. Written informed consent are acquired.

Exclusion criteria

1. Previously received stem cell transplantation.
2. Women with pregnant, lactating or not to take contraceptive measures.
3. Severe acute infection or suppurative and chronic infection that wound not healing.
4. Severe heart failure.
5. Suffering from mental disorders and poor compliance.
6. Other situations that investigators consider as contra-indication for this study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Treatment group

Experimental group

Treatment:

Other: Hematopoietic stem cell transplantation